Haloperidol

Delirium, Schizophrenia, Schizophrenia + 9 more

Treatment

2 FDA approvals

20 Active Studies for Haloperidol

What is Haloperidol

Haloperidol

The Generic name of this drug

Treatment Summary

Haloperidol is a medication used to reduce symptoms of psychotic disorders, such as schizophrenia. It blocks the dopamine receptors in the brain, particularly in the mesolimbic and mesocortical systems, which helps to reduce psychotic symptoms. Haloperidol is also used off-label to treat Huntington’s disease and intractable hiccups. It has been found to be effective in reducing hallucinations, aggression/hostility, disorganized speech, psychomotor agitation and other psychotic symptoms. However, it can cause movement disorders, sedation, weight gain, and prolactin changes. Haloperidol may

Haldol

is the brand name

image of different drug pills on a surface

Haloperidol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Haldol

Haloperidol

1971

300

Approved as Treatment by the FDA

Haloperidol, otherwise known as Haldol, is approved by the FDA for 2 uses which include Gilles de la Tourette's Syndrome and Tourette Syndrome .

Gilles de la Tourette's Syndrome

Helps manage Gilles de la Tourette's Syndrome

Tourette Syndrome

Helps manage Gilles de la Tourette's Syndrome

Effectiveness

How Haloperidol Affects Patients

Haloperidol is an antipsychotic drug that is effective in managing the positive symptoms of schizophrenia, such as hallucinations, hearing voices, and agitated behavior. However, it can cause movement problems, tiredness, weight gain, and other side effects.Haloperidol is generally better at causing fewer side effects than the lower potency first-generation antipsychotics, but it is more likely to cause movement problems. Taking too much haloperidol can cause an irregular heartbeat and even sudden death. In some cases, a serious condition called Neuroleptic Malignant Syndrome (NMS) can also occur. Symptoms of NMS include

How Haloperidol works in the body

Haloperidol works by blocking dopamine receptors in the brain, which can help reduce the symptoms of psychosis. It mainly blocks D2 dopamine receptors, but also has some effect on other receptors. It's believed that this blocking stops the overproduction of dopamine, which is thought to cause schizophrenia. Haloperidol also blocks receptors in the brainstem, which makes it an effective antiemetic. However, it has a strong binding to the D2 receptor, which can lead to unpleasant and long-lasting side effects known as extrapyramidal symptoms. For this reason, newer antipsychotic medications have been developed which have a lower

When to interrupt dosage

The recommended measure of Haloperidol is contingent upon the diagnosed situation, including Palliative Care, violent response and phencyclidine. The amount of dosage is delineated in the accompanying table, depending on the method of administration.

Condition

Dosage

Administration

Schizophrenia

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Tourette Syndrome

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Obsessive-Compulsive Disorder

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Severe Disruptive Behaviour Disorders

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Aggression

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

phencyclidine

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Nausea

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Palliative Treatment

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Huntington Disease

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Delirium

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

severe Hyperactivity

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Schizophrenia

5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL

, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Solution, concentrate, Solution, concentrate - Oral, Oral, Tablet, Tablet - Oral, Injection, Injection - Intramuscular, Solution, Solution - Intramuscular, Liquid - Intramuscular, Liquid, Solution - Oral

Warnings

Haloperidol has six contraindications and should not be combined with the ailment listed in the table below.

Haloperidol Contraindications

Condition

Risk Level

Notes

Coma

Do Not Combine

Asthma

Do Not Combine

Parkinson's Disease

Do Not Combine

Mental Depression

Do Not Combine

Basal Ganglia Lesions

Do Not Combine

Mental Depression

Do Not Combine

There are 20 known major drug interactions with Haloperidol.

Common Haloperidol Drug Interactions

Drug Name

Risk Level

Description

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Haloperidol.

Amisulpride

Major

Haloperidol may increase the antipsychotic activities of Amisulpride.

Azelastine

Major

Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cariprazine

Major

The metabolism of Cariprazine can be decreased when combined with Haloperidol.

Eliglustat

Major

The metabolism of Eliglustat can be decreased when combined with Haloperidol.

Haloperidol Toxicity & Overdose Risk

The average toxic dose of this drug in rats when taken orally is 71mg/kg.

image of a doctor in a lab doing drug, clinical research

Haloperidol Novel Uses: Which Conditions Have a Clinical Trial Featuring Haloperidol?

285 active clinical trials are currently in progress to assess the potential of Haloperidol in providing relief from Obsessive-Compulsive Disorder, Palliative Care and Phencyclidine intoxication.

Condition

Clinical Trials

Trial Phases

Schizophrenia

83 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Obsessive-Compulsive Disorder

61 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1

Schizophrenia

33 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Huntington Disease

3 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Aggression

1 Actively Recruiting

Not Applicable

Nausea

0 Actively Recruiting

Severe Disruptive Behaviour Disorders

1 Actively Recruiting

Phase 2

Tourette Syndrome

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Delirium

20 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1

phencyclidine

0 Actively Recruiting

severe Hyperactivity

0 Actively Recruiting

Haloperidol Reviews: What are patients saying about Haloperidol?

5

Patient Review

12/5/2012

Haloperidol for Schizophrenia

The generic didn't work for me, haloperidol is the right one.

4.7

Patient Review

3/17/2012

Haloperidol for Mental Disorder with Loss of Normal Personality & Reality

Haldol was great for my severe mania four years ago. It helped me a lot, but I experienced some drooling, the "Haldol shuffle," and my legs would jerk when I woke up. This time around, though, I haven't had any EPS side effects at all!

4.7

Patient Review

6/24/2011

Haloperidol for Nausea and Vomiting caused by Cancer Drugs

4.3

Patient Review

11/1/2014

Haloperidol for Schizophrenia

Haldol worked well for me, but I experienced some side effects like restless and pain in my legs. It's unclear if the drug was the cause of these problems.

4.3

Patient Review

9/28/2013

Haloperidol for Schizophrenia

This medication works well for me, with the only notable side effect being akithisia.

4.3

Patient Review

8/30/2020

Haloperidol for Schizophrenia

I have schizoaffective disorder and this medication has helped me in more ways than one. I'm much more functional now and things that used to bother me don't seem to phase me as much.

4.3

Patient Review

10/10/2011

Haloperidol for Schizophrenia

Simple to take and does the job.

3

Patient Review

12/31/2011

Haloperidol for Problem Behavior

This treatment can cause aggression in some people. I experienced this side effect and it was quite unpleasant.

2.7

Patient Review

9/23/2012

Haloperidol for Schizophrenia

I felt like a zombie.

2.3

Patient Review

2/20/2021

Haloperidol for Mental Disorder with Loss of Normal Personality & Reality

I had a severe reaction to this drug that sent me into anaphylactic shock and back to the hospital.

1.7

Patient Review

2/24/2011

Haloperidol for Psychosis caused by a Disease

1.7

Patient Review

10/9/2011

Haloperidol for Psychosis caused by a Disease

I experience a lot of pain in my legs and back.

1.3

Patient Review

2/5/2013

Haloperidol for Delirium

The side effects of this drug (tremors, anxiety, and high blood pressure) were really bad. I was better off without it.

1

Patient Review

12/28/2011

Haloperidol for Nausea and Vomiting caused by Cancer Drugs

My father was prescribed this drug for Alzheimers. It does not seem to work. Is this drug effective for people with Alzheimer's Disease?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about haloperidol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is haloperidol?

"Haloperidol is a type of medication known as a conventional antipsychotic. It works by decreasing abnormal excitement in the brain."

Answered by AI

What are some side effects of haloperidol?

"The effects listed above may occur when taking this medication. If they persist or worsen, notify your doctor or pharmacist. Dizziness and lightheadedness may cause falls."

Answered by AI

What is haloperidol drug used for?

"Haloperidol is a medication used to treat psychotic disorders, conditions that cause difficulty distinguishing between reality and what is not real."

Answered by AI

How does haloperidol make you feel?

"This medicine may cause some people to feel dizzy, drowsy, or have trouble thinking or controlling their body movements, which could lead to falls, fractures, or other injuries. You may feel drowsy or less alert when you wake up, even if you took haloperidol at bedtime."

Answered by AI

Clinical Trials for Haloperidol

Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Haloperidol clinical trials?

We made a collection of clinical trials featuring Haloperidol, we think they might fit your search criteria.
Go to Trials
Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX

Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Recruiting
Has No Placebo

The University of Iowa

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Multimodal Intervention for Bipolar Disorder

18 - 35
All Sexes
Hamilton, Canada

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.

Recruiting
Has No Placebo

St. Joseph's Healthcare Hamilton

Have you considered Haloperidol clinical trials?

We made a collection of clinical trials featuring Haloperidol, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN

The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.

Waitlist Available
Has No Placebo

Vanderbilt Psychiatric Hospital

Heather Ward, MD

Have you considered Haloperidol clinical trials?

We made a collection of clinical trials featuring Haloperidol, we think they might fit your search criteria.
Go to Trials